I believe your problem in saying we're overbought is the question of what should the market cap of a company in this position be. I'll contend that the cream has blockbuster potential, it will shortly be in Phase 2 trials, and with patent approval the company owns the intellectual property. I would contend that any other biotech in a similar position would have a market cap somewhere in the range of $100 to $500 million. Our current market cap is $30 million